Restricted accessResearch articleFirst published online 1989-9
Immunobiology and Immunotherapy of Cancer Metastases Ten-Year Studies in an Animal Model Resulting the Design of an Immunotherapy Procedure now under Clinical Testing
Failure of cancer therapy can most often be attributed to metastasis, which changes a localised disease into a systemic one. Animal models have contributed to improved understanding of metastasis formation, dissemination and treatment, and in this review immunological findings from the highly metastatic murine ESb lymphoma model are presented. Insights gained from this research can be applied to the design of new immunotherapy protocols for the treatment of many human cancers. The development and application of active specific immunotherapy (ASI) are described.
Get full access to this article
View all access options for this article.
References
1.
SchirrmacherV., Cancer metastasis: Experimental approaches, theoretical concepts and impacts for treatment strategies. Adv. Cancer Res. 43, 1–73 (1985).
2.
SchirrmacherV., Commentary. Shifts in tumour cell phenotypes induced by signals from the microenvironment: Relevance for the immunobiology of cancer metastasis. Immunobiology157, 89–98 (1980).
3.
PohlJ., Radler-PohlA. and SchirrmacherV., A model to account for the effects of oncogenes, tpa and retinoic acid on the regulation of genes involved in metastasis. Cancer Met. Rev. 7, 347–356 (1988).
4.
SchirrmacherV., ShantzG., ClauerK., KomitowskiD., ZimmermannH.-P. and Lohmann-MatthesM.-L., Tumour metastases and cell-mediated immunity in a model system in dba/2 mice. I. Tumour invasiveness in vitro and metastases formation in vivo. Int. J. Cancer23, 233–244 (1979).
5.
LarizzaL., SchirrmacherV. and PflügerE., Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumour line with a bone-marrow derived macrophage. J. Exp. Med. 160, 1579–1584 (1984).
6.
LarizzaL., SchirrmacherV, GrafL., PflügerE., Peres-MartinezM. and StöhrM., Suggestive evidence that the highly metastatic variant ESb of the T cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Int. J. Cancer34, 699–707 (1984).
7.
ErkellL. J. and SchirrmacherV., Quantitativein vitro assay for tumour cell invasion through extracellular matrix or into protein gels. Cancer Res. 48. 6933–6937 (1988).
8.
VlodavskyI., SchirrmacherV., AriavV. and FuksZ., Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: Attachment, invasion and morphological appearance. Invasion and Metastasis3, 81–97 (1983).
9.
Bar-NerM., MayerM., SchirrmacherV and VlodavskyI., Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix. J. Cell Physiol. 128, 299–306 (1986).
10.
SchirrmacherV., FogelM., RussmannE., BossletK., AltevogtP. and BeckL., Antigenic variation in cancer metastasis: Immune escape versus immune control. Cancer Met. Rev. 1, 241–274 (1982).
11.
StorchE., KirchnerH. and SchirrmacherV., Prolonged survival of mice against the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination withCorynebacterium parvum. Cancer Immunol. Immunother. 23, 179–184 (1986).
12.
SchirrmacherV., Tumour metastases and cell-mediated immunity in a model system in dba/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B10.D2 mice. Int. J. Cancer24, 80–86 (1979). Europ. J. clin. Nutrition43, 367–377 (Europe I).
13.
SchirrmacherV., BossletK., ShantzG., ClauerK. and HübschD., Tumour metastases and cell-mediated immunity in a model system in dba/2 mice. IV. Antigenic differences between the parental tumour line and its metastasising variant. Int. J. Cancer23, 245–252 (1979). Europ. J. clin. Nutrition43, 379–390 (Europe II).
14.
BossletK., SchirrmacherV. and ShantzG., Tumour metastases and cell-mediated immunity in a model system in dba/2 mice. VI. Similar specificity patterns of protective anti-tumour immunityin vivo and of cytolytic T cells in vitro. Int. J. Cancer24, 303–313 (1979).
15.
AltevogtP., LeidigS. and Heckl-ÖstreicherB., Resistance of metastatic tumour variants to tumour-specific cytotoxic T lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells. Cancer Res. 44, 5305–5313 (1984).
16.
BossletK. and SchirrmacherV., Escape of metastasising clonal tumour cell variants from tumour-specific cytolytic T lymphocytes. J. Exp. Med. 154, 557–561 (1981).
17.
ZangemeisterU., ThiedeK. and SchirrmacherV., Recruitment and activation of tumour-specific immune T cells in situ: functional studies using a sponge matrix model. Int. J. Cancer43, 310–316 (1989).
18.
ThiedeK., MomburgF., ZangemeisterU., SchlagP. and SchirrmacherV., Growth and metastasis of human tumours in nude mice following tumour-cell inoculation into a vascularised polyurethane sponge matrix. Int. J. Cancer42, 939–945 (1988).
19.
ZangemeisterU., KyewskiB. and SchirrmacherV., Recruitment and activation of tumour-specific immune T cells in situ: CD8+ cells predominate the secondary response in sponge matrices and exert both dth-like and ctl activity. J. Immunol. (in press).
20.
von HoegenP., WeberE. and SchirrmacherV., Modification of tumour cells by a low dose of Newcastle disease virus: Augmentation of the tumour-specific T cell response in the absence of an anti-viral response. Eur. J. Immunology18, 1159–1166 (1988).
21.
SchildH.-J., KyewskiB., von HoegenP. and SchirrmacherV., CD4+ helper T cells are required for resistance to a highly metastatic murine tumour. Eur. J. Immunol. 17, 1863–1866 (1987).
22.
BossletK. and SchirrmacherV., High-frequency generation of new immunoresistant tumour variants during metastasis of a cloned murine tumour line (ESb). Int. J. Cancer29, 195–202 (1982).
23.
AltevogtP., von HoegenP. and SchirrmacherV, Immunoresistant metastatic tumour variants can reexpress their tumour antigen after treatment with dna methylation-inhibiting agents. Int. J. Cancer38, 707–711 (1986).
24.
von HoegenP., HeicappellR., GriesbachA., AltevogtP. and SchirrmacherV., Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumour cells. III. Postoperative activation of tumour-specific ctlp from mice with metastases requires stimulation with the specific antigen plus additional signals. Invasion and Metastasis9, 117–133 (1989).
25.
SchirrmacherV., Postoperative activation of tumour specific T cells as a means to achieve immune control of minimal residual disease, inAccomplishments in Cancer Research 1986, FortnerJ. G. and RhoadsJ. E.(Eds), pp. 218–232. General Motors Cancer Research Foundation, Philadelphia (1986).
26.
SchirrmacherV, AhlertT., HeicappellR., AppelhansB. and von HoegenP., Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy. Cancer Rev. 5, 19–49 (1986).
27.
AltevogtP., von HoegenP. and SchirrmacherV., The effects of mutagens on the immunogenicity and antigenicity of murine high or low metastatic lymphomas, inCarcinogenesis and Tumour Progression(C. Lapis and Eckhard (Eds), Vol. 4, pp. 301–310. Karger, Basel (1987).
28.
von HoegenP., AltevogtP. and SchirrmacherV., New antigen presented on tumour cells can cause rejection without influencing the frequency of tumour-specific cytolytic T cells. Cell. Immunol. 109, 338–348 (1987).
29.
BoonT., Antigenic tumour cell variants obtained with mutagens. Adv. Cancer Res. 39, 121–151 (1983).
30.
MatzkuS., KirchgessnerH. and SchirrmacherV., Antibody targeting to the murine lymphoma ESb-mp: Increased accumulation due to reduced internalisation into lymphoma cells as compared to normal lymphoid cells. Int. J. Cancer41, 108–114 (1988).
31.
AltevogtP., KohlU., von HoegenP., LangE. and SchirrmacherV., Antibody 12–15 cross-reacts with mouse Fc receptors and CD2: Study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein. Eur. J. Immunol. 19, 341–346 (1989).
32.
PflügerE., LangE., BenkeR., Heckl-ÖstreicherB., AltevogtP. and SchirrmacherV., Generation of adhesive tumour variants: Chromosomal changes, reduction in malignancy and increased expression of a distinct membrane glycoprotein. Clin. Exp. Met. 6, 485–499 (1988).
33.
BenkeR., LangR., KomitowskiD., MutoS. and SchirrmacherV., Changes in tumour cell adhesiveness affecting speed of dissemination and mode of metastatic growth. Invasion and Metastasis8, 159–176 (1988).
34.
KobayashiH., Viral xenogenisation of intact tumour cells. Adv. Cancer Res. 30, 279–299 (1979).
35.
SuzukiY., SuzukuT., MatsunagaM. and MatsumotoM., Gangliosides as paramyxovirus receptor. Structural requirement of sialo-oligosaccharides in receptors for haemag- glutinating virus of Japan (Sendai virus) and Newcastle disease virus. J. Biochem. 97, 1189 (1985).
36.
HeicappellR., SchirrmacherV., von HoegenP., AhlertT. and AppelhansB., Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumour cells. Int. J. Cancer37, 569–577 (1986).
37.
SchildH.-J., von HoegenP. and SchirrmacherV., Modification of tumour cells by a low dose of Newcastle disease virus: II. Augmented tumour specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. Cancer Immunol, Immunother. 28, 22–28 (1988).
38.
SchirrmacherV. and HeicappellR., Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumour cells. II. Establishment of specific systemic anti-tumour immunity. Clin. Exp. Met. 5(2), 147–156 (1987).
39.
SchirrmacherV., von HoegenP., SchlagP., LeibrichW., LehnerB., SchumacherK., AhlertT. and BastertG., Active specific immunotherapy with autologous tumour cell vaccines modified by Newcastle disease virus: Experimental and clinical studies, inCancer Metastasis. SchirrmacherV. and Schwartz-AlbiezR.(Eds), Springer-Verlag, Berlin (1989).
40.
CassellW. A., MurrayD. R. and PhillipsH., A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer52, 856–860 (1983).
41.
HooverH. C.Jr., SurdykeM. G., DangelR. B., PetersL. C. and HannaM. G., Prospectively randomised trial of adjuvant active specific immunotherapy for human colorectal cancer. Cancer55, 1263–1243 (1985).
42.
HollinsheadA., StewartT. H. M., TakitaH., DalbowM. and ConcannonJ., Adjuvant specific active lung cancer immunotherapy trials. Tumour-associated antigens. Cancer60, 1249–1262 (1987).
43.
TallbergT., KalinaT., HalttunenP., TykkäH., MahlbergK., MatousB. and SundellB., Postoperative specific immunotherapy with supportive measures in patients suffering from recurrent metastasised melanoma. J. Surg. Oncol. 33, 115–119 (1986).
